Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Follow-Up Questions
¿Quién es el CEO de Aditxt Inc?
Mr. Amro Albanna es el Chairman of the Board de Aditxt Inc, se unió a la empresa desde 2017.
¿Qué tal es el rendimiento del precio de la acción ADTX?
El precio actual de ADTX es de $0.2439, ha increased un 13.39% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Aditxt Inc?
Aditxt Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Aditxt Inc?
La capitalización bursátil actual de Aditxt Inc es $1.2M
¿Es Aditxt Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Aditxt Inc, incluyendo 2 fuerte compra, 4 compra, 2 mantener, 0 venta, y 2 fuerte venta
